tetano
Editor, Senior Moderator
Infect Dis Ther
. 2020 Sep 16.
doi: 10.1007/s40121-020-00338-x. Online ahead of print.
Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All
Grant W Waterer[SUP] 1 2 [/SUP], Jordi Rello[SUP] 3 4 5 [/SUP]
Affiliations
Abstract
COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.
Keywords: ARDS; Coronavirus; Covid-19; Pneumonia; Precision medicine; RCT; SARS; Therapy.
. 2020 Sep 16.
doi: 10.1007/s40121-020-00338-x. Online ahead of print.
Steroids and COVID-19: We Need a Precision Approach, Not One Size Fits All
Grant W Waterer[SUP] 1 2 [/SUP], Jordi Rello[SUP] 3 4 5 [/SUP]
Affiliations
- PMID: 32936438
- DOI: 10.1007/s40121-020-00338-x
Abstract
COVID-19 is a new infectious disease causing severe respiratory failure and death for which optimal treatment is currently unclear. Many therapies have been proven to be ineffective; however, promising findings related to corticosteroid therapy have been published. Analysis of published data including in this issue suggests that therapy with corticosteroids in the range of 6 mg of dexamethasone (or equivalent) per day likely has a positive effect in patients requiring mechanical ventilation but there remains considerable doubt in patients over the age of 70, in patients with diabetes and patients with milder disease. Clinicians must consider the individual potential risks and benefits of corticosteroid in patients with COVID-19 rather than routinely using them until more data is available.
Keywords: ARDS; Coronavirus; Covid-19; Pneumonia; Precision medicine; RCT; SARS; Therapy.